Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Strategy for retroviral immunotherapy

A technology of retroviruses and subjects, applied in the direction of retroRNA viruses, viruses, antiviral agents, etc., can solve problems such as the lack of an effective vaccine strategy for HIV infection, and achieve a complete therapeutic effect

Inactive Publication Date: 2009-01-28
免疫援助有限公司
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite these efforts, no effective vaccine strategy has been developed for the treatment of HIV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Strategy for retroviral immunotherapy
  • Strategy for retroviral immunotherapy
  • Strategy for retroviral immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] To demonstrate the present invention, a murine AIDS model was used.

[0131] Murine AIDS (MAIDS) pathology induced by LP-BM5 murine leukemia virus (MuLV) in susceptible mice is a useful tool for studying the mechanisms of retrovirus-induced immunodeficiency. This MAIDS animal model exhibits many of the features of human AIDS. Infection of susceptible strains, such as C57BL / 6 mice with LP-BM5, leads to the development of chronic splenomegaly, hypergammaglobulinemia, and T- and B-cell immunodeficiency. In vitro, there is progressive impairment of the ability of T and B cells to respond to mitogenic or specific antigenic stimulation. In vivo, infected mice became increasingly susceptible to invasion with various opportunistic organisms and developed B-cell lymphomas. Mortality was first observed at 8-10 weeks post-infection (pi), and all mice died within 24 weeks (Figure 1). These changes in immune function reflect complex changes in the phenotype and function of all co...

Embodiment 2

[0172] Human patients with HIV infection were placed on HAART for at least 6 months before withdrawal of treatment. Viral load and c-reactive protein levels in samples obtained during and after HAART were determined using standard techniques.

[0173] as in Figure 18 As seen in , the results showed an increase in viral load after HAART ended. Then the viral load decreases due to the activity of effector cells, and then increases again due to the regulation of effector cells. c-reactive protein levels approximately reflect viral load, suggesting that measurement of this protein can be used as a marker of effector cell viability as well as viral load.

Embodiment 3

[0175] Vaccines containing retroviral antigenic polypeptides are administered to human patients with HIV infection. Examples of such vaccines are discussed in Dennehy (2001) and Moore et al. (2001).

[0176]Following vaccine administration, c-reactive protein levels were analyzed as generally described in Example 2. Preferably, the level of c-reactive protein is determined at least every 24 hours. Naturally, the patient should be checked for any signs, eg, other viral or bacterial infections that could lead to elevated c-reactive protein levels. In the absence of such signs, continue to monitor C-reactive protein levels until they peak and begin to decrease. As an indication of effector cell modulation, anti-CD4+ antibodies are administered to the subject at a standard dose, eg, 300 mg, approximately when c-reactive protein levels begin to decrease.

[0177] The patient is then continued to be monitored for HIV markers, such as determination of viral load. Treatment may be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention points out generating at least two immune cell colonies at responding to retrovirus infecting mammals. In particular, the immune system of the mammals infected by the retrovirus can enhance the immune response of the retrovirus through a group of cells generally named as effector cells, however, the second immune cell colony is generated synchronously to regulate the effector cells generally named as regulation cells (or suppressor cell), so as to restrict the capability of the mammals for effectively controlling or eliminating the retrovirus infection. Therefore, the invention uses these observation results to provide a method for treating the mammals infected by the retrovirus. Moreover, the invention has found that an acute inflammatory index can be used for detecting and monitoring the response of the effector cells to the retrovirus antigen.

Description

[0001] This application is a divisional application of an invention patent application with an application date of February 18, 2003, an application number of 03808873.8, and an invention title of "Strategy for Retroviral Immunotherapy". Field of invention: [0002] The present invention provides a method of treating a retroviral infection in a mammalian subject. More specifically, the invention provides a method of treating a retroviral infection that causes an immunodeficiency-associated disease in a human subject. Background of the invention: [0003] Human immunodeficiency virus (HIV) induces persistent and progressive infection, which in most cases leads to the development of acquired immunodeficiency syndrome (AIDS). There are at least 2 different types of HIV: HIV-1 and HIV-2. In humans, HIV infection ultimately leads to immunocompromise, opportunistic infections, neurological dysfunction, tumor growth, and eventually death. [0004] HIV is a member of the lentiviru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/50A61K39/21A61K45/06A61P31/18A61K31/475C07D519/04A61K39/00A61K39/39A61P31/14
CPCC12N2740/16034A61K39/21A61K2039/545A61K2039/53A61K45/06A61K2039/542A61K39/12A61P31/14A61P31/18
Inventor M·L·阿什当
Owner 免疫援助有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com